# IBEX Limited (IBEX) · Edgar & Edgarette company card

> IBEX Limited (IBEX) grew revenue 15.4% in FY2026 to $644 million, operating margin 8.5% against a 7.7% median for computer processing & data preparation, equity 55.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1720420 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/IBEX) · [JSON](https://www.pops4.com/boards/company/IBEX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $644M |
| Revenue growth, 1 year | 15.4% |
| Revenue growth per year | 6.9% |
| Operating margin | 8.5% (prior year 8.3%) |
| Net margin | 7.2% |
| Operating cash flow | $59M |
| Capital spending | $28M |
| Free cash flow | $31M |
| Cash | $33M |
| Long-term debt | $2M |
| Total assets | $309M |
| Total equity | $170M |
| Equity ÷ assets | 55.1% |
| Return on equity | 27.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 5.24 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $644.1M (FY2026), total debt $1.7M. Experience: revenue up 15.4% on the year, up 6.9% a year over 4 years; operating margin 8.5%, up from 8.3%. Soundness: equity 55.1% of assets, return on equity 27.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $613.0M and $804.5M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $572.3M to $864.2M. A statistical range, not company guidance. Against peers (35 filers, $50M+ revenue, services-computer processing & data preparation): operating margin 8.5% against a 7.7% median; growth 15.4% against 10.2%.

Range logged 2026-09-24, receipt ba28f1974aa2b3f7, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2025-12-19 ([filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042025000054/0001720420-25-000054-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-28 · [filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042026000030/0001720420-26-000030-index.htm)
- 10-K · filed 2026-09-10 · [filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042026000025/0001720420-26-000025-index.htm)
- 8-K · filed 2026-09-10 · 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042026000024/0001720420-26-000024-index.htm)
- 8-K · filed 2026-05-13 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042026000014/0001720420-26-000014-index.htm)
- 10-Q · filed 2026-05-06 · [filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042026000011/0001720420-26-000011-index.htm)
- 8-K · filed 2026-05-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1720420/000172042026000010/0001720420-26-000010-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001720420.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1720420

## Cite

POPS4, Edgar & Edgarette: IBEX Limited (IBEX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/IBEX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.